<DOC>
	<DOC>NCT00105456</DOC>
	<brief_summary>This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.</brief_summary>
	<brief_title>A Study of Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Signed Informed Consent document (unless the IRB has granted a waiver of consent) Signed Authorization for the Use and Disclosure of Health Information document HER2positive breast cancer Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment Availability of cancerspecific historical data points in the patient's medical records There are no exclusion criteria for participation in this trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>HER2-Positive Metastatic Breast Cancer</keyword>
	<keyword>HER2</keyword>
</DOC>